Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a new formulation of all-trans retinoic acid bound to polyvinyl alcohol showed reduced skin inflammation and sustained drug release for up to six days compared to free ATRA in vitro and in vivo.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This review identified two promising therapeutic targets for drug repurposing to treat refractory angina in patients with angina pectoris without obstructive coronary artery disease: endothelin-1 receptor blockers and soluble guanylate cyclase stimulators.

The authors concluded that newly synthesized N-acyl-L-tryptophanyl-isoleucine amides showed high anxiolytic activity in animal models, comparable to diazepam, through interaction with the TSPO receptor.

This review discusses current treatments for benign prostatic hyperplasia and reports on the cost-effectiveness of alpha1-selective adrenergic receptor antagonists compared to other pharmacologic and invasive therapies without presenting new clinical results.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

In this case series conducted in Austrian dermatology clinics, tralokinumab was found to be a well-tolerated and effective long-term treatment for adults with moderate-to-severe atopic dermatitis, with improvements in eczema severity and symptom suppression maintained over up to three years.

This article reviews the use of 5alpha-reductase inhibitors for managing benign prostatic hyperplasia and reports no new clinical results.

This study found that topical phenylephrine, an α1-AR agonist, significantly reduced hair shedding and increased epilation force threshold in women experiencing traction alopecia during cosmetic procedures.

This study found that several preservatives, including triclocarban and triclosan, showed potential endocrine-disrupting effects on various nuclear receptors in both in silico and in vitro models.

This study found that camphor and similar compounds depress neural activity in rat mechanoreceptors, suggesting that their effects may not be mediated through TRP channels.

This review discusses the role of the TRPV4 channel in skin physiology and pathology, highlighting its potential as a therapeutic target for skin disorders, but reports no new clinical results.

This study found that arginine vasotocin is evolutionarily conserved across diverse taxa and may play roles in neuroendocrine, immune, and stress signaling, with potential antimicrobial applications.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

This study evaluated Tridax procumbens extracts for their in-vitro alpha amylase inhibitory activity compared to standard antidiabetic agents, suggesting potential benefits for diabetes management.

This study found that activation of the TRPV3 ion channel inhibits human hair growth by affecting hair follicles and outer root sheath keratinocytes.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

Tralokinumab may help improve symptoms of atopic dermatitis and alopecia areata.

In this study, the authors reported that dutasteride significantly reduced total remission time for COVID-19 symptoms in men compared to placebo, especially for fatigue and loss of taste or smell.

This review discusses the pharmacological properties and therapeutic potential of K+ channel opening compounds, noting their prospective use in treating cardiovascular and respiratory conditions, but reports no new results.

This protocol outlines a planned Cochrane Review to evaluate the effects of 5-alpha-reductase inhibitors on lower urinary tract symptoms caused by benign prostatic obstruction, and it reports no new findings.

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.

This study found that bis-benzylisoquinoline and Amaryllidaceae alkaloids, especially aromoline, show potential as antiviral agents, suggesting they could serve as foundations for developing new treatments against coronaviruses by enhancing the understanding of their structure-activity relationships.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

In this study, Chinese children with central precocious puberty receiving 6-monthly injections of triptorelin showed luteinizing hormone suppression and slowed development of sexual characteristics over 12 months, without severe adverse events, suggesting it may be an effective treatment option for this population.

This study found that in a rat model, 14,15-EET may alleviate central poststroke pain by enhancing thalamic inhibition through neurosteroid signaling, potentially outperforming gabapentin in early-stage treatment.